Investor Relations

With a world class scientific foundation, a capital efficient development plan, and founders with deep expertise in oncology and global biotech leadership, we are raising a $10M seed round to complete our ongoing Phase I study and prepare for the initiation of Phase II – super critical value inflection point. Join us in building a company that can change the trajectory of cancer treatment